Related Experiment Video
Updated: Aug 25, 2026
Elevated Plus Maze for Mice
Published on: December 21, 2008
Meropenem: evidence of lack of proconvulsive tendency in mice
Abstract:
The proconvulsive tendency of the novel carbapenem, meropenem was compared to that of imipenem, alone and in combination with cilastatin. The potentiation of metrazole-induced convulsions in mice was measured. Both imipenem and imipenem/cilastatin caused significant potentiation of metrazole-induced convulsions at a dose of 200 mg/kg, i.v. In contrast, meropenem (50-400 mg/kg, iv) failed to exhibit any significant potentiation of metrazole-induced seizures.
Insights
Meropenem, a novel carbapenem antibiotic, did not increase seizure risk in mice. Unlike imipenem, meropenem showed no proconvulsive effects, suggesting a potentially safer neurological profile for this important antibiotic class.
Area of Science:
- Pharmacology
- Neuroscience
- Infectious Diseases
Background:
- Carbapenem antibiotics are crucial for treating severe bacterial infections.
- Some carbapenems, like imipenem, are associated with neurological side effects, including seizures.
- Meropenem is a newer carbapenem with a potentially different safety profile.
Purpose of the Study:
- To compare the proconvulsive potential of meropenem with imipenem.
- To evaluate the influence of cilastatin on imipenem's proconvulsive effects.
- To assess the safety of meropenem regarding central nervous system side effects.
Main Methods:
- The study utilized a mouse model to measure the potentiation of metrazole-induced convulsions.
- Different doses of meropenem (50-400 mg/kg, i.v.) were administered.
- Imipenem, alone and with cilastatin, was used as a comparator.
Main Results:
- Imipenem and imipenem/cilastatin significantly potentiated metrazole-induced convulsions at 200 mg/kg, i.v.
- Meropenem did not exhibit significant potentiation of seizures across the tested dose range (50-400 mg/kg, i.v.).
- This indicates a lack of proconvulsive activity for meropenem in this model.
Conclusions:
- Meropenem demonstrates a lack of proconvulsive tendency, unlike imipenem.
- The findings suggest meropenem may have a more favorable neurological safety profile.
- This is important for clinical use, especially in patients at risk for seizures.
